45 results about "Trimetazidine" patented technology

The combination of a HMG CoA reductase inhibitor like a statin, such as simvastatin, with a pFox inhibitor such as trimetazidine (“Simetazidine”) is particularly advantageous for treatment of end-stage complications, such as acute coronary syndrome (ACS) and chronic angina, especially in type II diabetics. The combination therapy is also useful in the treatment and/or prevention of chronic heart failure (CHF) and peripheral arterial disease (PAD). The combination of a nitric oxide (NO) mechanism with increased NO production with pFox inhibition simultaneously treats both the effect and the cause of angina. One or more oral hypoglycemic compounds (biguanides, insulin sensitizers, such as thiazolidinediones, α-glucosidase inhibitors, insulin secretagogues, and dipeptidyl peptidase IV inhibitors), protein kinase C (PKC) inhibitors, and acetyl-CoA carboxylase inhibitors can also be used in combination with the HMG CoA reductase inhibitors and/or pFox inhibitors, especially in type II diabetics, to control glucose levels and treat endothelial dysfunction. The drugs can be given in combination (e.g. a single tablet) or in separate dosage forms, administered simultaneously or sequentially. In the preferred form the statin is given in a dose of between 5 and 80 mg/day in two separate doses, and the pFox inhibitor is administered in a sustained or extended dosage formulation at a dose of 20 mg three times a day or 35 mg two times a day. The dose of the oral hypoglycemic, PKC inhibitor, or acetyl-CoA carboxylase inhibitor varies with the type of drug used.

The present invention relates to one kind of orally taken control released trimetazidine medicine composition and its preparation process. The trimetazidine medicine composition consists of trimetazidine or its physiologically acceptable salt in effective dosage and pharmaceutically acceptable medicine excipient capable of reaching release controlling osmotic pump effect. The medicine excipient is one or several selected from osmotic pressure active matter, permeation assistant, diluent, colorant, lubricant, moistener or adhesive, filming material, pore creating agent, plasticizer and solvent.

The invention discloses trimetazidine and a production method of hydrochloride thereof, which belongs to the technical field of chemical synthesis and is characterized by adopting 2,3,4-3-methoxybenzaldehyde and piperazine as raw materials. The method comprises the following steps of: adding a solvent, 2,3,4-3-methoxybenzaldehyde and anhydrous piperazine with the molar ratio of 1:1 to 1:3, and a nickel-based catalyst accounting for 3 to 10% of the mass percentage of the 2,3,4-3-methoxybenzaldehyde and the anhydrous piperazine to a pressure kettle; using nitrogen for purging before hydrogen is led in, with hydrogen pressure maintained within the range of 0.7MPa to 2.0MPa, reaction temperature within the range of 50 DEG C to 95 DEG C, reaction time within the range of 4 hours to 10 hours, and pH value regulated to 3 to 4; separating out organic phase; and recovering the solvent. The water phase is washed with chlorinated hydrocarbon extraction, and the pH value is regulated to 12, then the water phase is extracted with aromatic hydrocarbon, and the aromatic hydrocarbon in the aromatic hydrocarbon extraction liquid is steamed out, thus obtaining the trimetazidine. The invention has the advantages of low production cost, high yield, and good environmental protection.

The invention discloses a trimetazidine sustained-release mini-pill composition. The trimetazidine sustained-release mini-pill composition comprises sustained-release pills A and C or sustained-release pills A, B and C. The sustained-release pills A, B and C have different increased weights. The trimetazidine sustained-release mini-pill composition has the advantages that two or three types of film-controlled sustained-release mini-pills with different increased weights are proportionally mixed with one another to obtain the trimetazidine sustained-release mini-pill composition, accordingly, zero-order release effects can be realized by the trimetazidine sustained-release mini-pill composition, and the trimetazidine sustained-release mini-pill composition can be released in a long-acting and sustained manner.

The invention relates to a methods, compositions and kits for treating hyperglycemia and related disorders, such as type 2 diabetes mellitus, impaired glucose tolerance, diabetic retinopathy, diabetic nephropathy and diabetic neuropathy, and to methods, compositions and kits for treating erectile dysfunction. The methods comprise administering an inhibitor of fatty acid oxidation to a subject in need thereof. In some embodiments, trimetazidine and metformin or a phosphodiesterase 5 inhibitor are administered.

The present invention provides a pharmaceutical composition used for treating severe altitude sickness, characterized by a composition consisting of trimetazidine or pharmaceutically acceptable salt thereof and L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, and the weight ratio of the above being 1:200.

The present invention discloses a slow-release agent for increasing hypoxia tolerance; the slow-release agent is a composition formed by combining trimetazidine or pharmaceutically acceptable salt thereof and L-carnitine or derivative thereof or pharmaceutically acceptable salt thereof, according to the ratio 1:1.6-6400.

The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof.

The invention relates to a preparation method of trimetazidine, belonging to the preparation field of medicine compound. The method comprises the steps of: by taking 2, 3, 4-trimethoxy benzaldehyde and piperazine as raw materials and formic acid as a catalyst; adding a solvent and formic acid in the 2, 3, 4-trimethoxy benzaldehyde and the piperazine for reaction; removing the solvent by steaming, and adjusting the pH value of reaction liquid to be 11-13; and then, carrying out reflux, acidification and rotary steaming to obtain the trimetazidine. In the method, the reductive amination reaction is adopted and the trimetazidine is synthesized in one step under the condition that the formic acid is taken as the catalyst, and the yield reaches up to 83-92%; meanwhile, precious metal palladium catalyst is not used, so that the synthesis cost is reduced. The LiAlH4 and NaBH4 which are high in danger are not used, so that the experimental safety is improved; and the method is beneficial to the large-scale production of the trimetazidine.

There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.

The invention discloses a method convenient for myocardial metabolism development. The method comprises the following steps of S1, determining a research population; S2, regulating blood sugar and performing developing; S3, evaluating image quality; S4, performing visual analysis; S5, performing quantitative analysis; S6, performing quantitative analysis on heart function and myocardial viability;and S7, performing counting. According to the method, trimetazidine can increase the glucose metabolism level of normal or ischemic myocardium of a diabetic patient to different extents, remarkably improve the image quality of 18F-FDG myocardial metabolism imaging (MMI), potentially improve the accuracy of gated PET quantitative parameter measurement, is safe and effective, and is combined with an oral glucose load/intravenous injection insulin method for use. Compared with a normal blood sugar hyperinsulinism holder technology, the method disclosed by the invention is more convenient to operate, and clinical application and popularization are facilitated.

Methods are provided for preventing, reducing, and/or treating contrast-induced acute kidney injury which include administering an inhibitor of fatty acid oxidation to a patient in need thereof. Also provided are methods involving use of trimetazidine or pharmaceutically acceptable salts thereof for the prevention and/or treatment of contrast-induced acute kidney injury. Methods are also provided for preventing and/or treating contrast-induced acute kidney injury which include administration of one or more of trimetazidine, etomoxir, oxfenicine, perhexiline, mildronate, or ranolazine, or pharmaceutically acceptable salts of any of the preceding.

The invention discloses a medicine composition for treating heart failure and application thereof. The medicine composition is prepared from an active ingredient and medicinal auxiliaries, wherein the active ingredient comprises (1) tortuosine and (2) trimetazidine or medicinal salt thereof. The medicine composition can be used for synergistically resisting myocardial apoptosis and protecting cardiac muscle mitochondria so as to achieve the aim of preventing and treating heart failure.

Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 compositions and at least one fatty acid metabolism inhibitor. In one embodiment, the CoQ10 compositions are lipid-containing compositions. The fatty acid metabolism inhibitor may be an inhibitor of fatty acid synthesis, storage, transport or degradation. The fatty acid metabolism inhibitor may also be a modulator of fatty acid structure, for example a fatty acid desaturase or elongase. The fatty acid inhibitor may inhibit any molecule involved in fatty acid metabolism, such as fatty acid synthase (FASN), carnitine palmitoyltransferase 1 (CPT-1), long-chain 3-ketoacyl-CoA thiolase, or stearoyl-CoA desaturase-1 (SCD-1). In embodiments, the fatty acid metabolism inhibitor may be C75, Etomoxir, trimetazidine or A939572.